IM Cannabis (IMCC) Income from Non-Controlling Interests (2020 - 2025)
IM Cannabis' (IMCC) quarterly Income from Non-Controlling Interests came in at $95266.0 in Q2 2025, up 130.51% year-on-year from $41327.5 in Q2 2024, and up 105.76% quarter-over-quarter from -$1.7 million in Q4 2024.
IM Cannabis (IMCC) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends
IM Cannabis' Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at $95266.0 for Q2 2025.
- On a quarterly basis, Income from Non-Controlling Interests rose 130.51% year-over-year to $95266.0 in Q2 2025; TTM through Jun 2025 was -$2.2 million, a 428.13% decrease from a year earlier, with the FY2025 full-year figure at -$248111.9, up 71.36% from the prior year.
- Income from Non-Controlling Interests advanced to $95266.0 in Q2 2025 per IMCC's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.0 million in Q1 2024 and bottomed at -$1.7 million in Q4 2024.
- The 5-year median for Income from Non-Controlling Interests is -$274427.4 (2023), against an average of -$256979.1.
- Biggest YoY gain for Income from Non-Controlling Interests was 468.32% in 2024; the steepest drop was 826.83% in 2024.
- Year by year, Income from Non-Controlling Interests stood at -$547401.9 in 2021, then slumped by 113.72% to -$1.2 million in 2022, then surged by 84.74% to -$178492.1 in 2023, then slumped by 826.83% to -$1.7 million in 2024, then surged by 105.76% to $95266.0 in 2025.
- Per Business Quant, the three latest IMCC Income from Non-Controlling Interests figures stand at $95266.0 (Q2 2025), -$1.7 million (Q4 2024), and -$317412.1 (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 95,266.05 |
| Dec 31, 2024 | -1.65 Mn |
| Sep 30, 2024 | -317,412.13 |
| Jun 30, 2024 | -312,197.01 |
| Mar 31, 2024 | 1.01 Mn |
| Dec 31, 2023 | -178,492.13 |
| Sep 30, 2023 | 146,948.30 |
| Jun 30, 2023 | -183,879.76 |
| Mar 31, 2023 | -274,427.35 |
| Dec 31, 2022 | -1.17 Mn |
| Sep 30, 2022 | 585,027.39 |
| Jun 30, 2022 | -271,381.87 |
| Mar 31, 2022 | -737,370.03 |
| Dec 31, 2021 | -547,401.90 |
| Sep 30, 2021 | 728,473.34 |
| Jun 30, 2021 | -373,408.97 |
| Mar 31, 2021 | -914,934.78 |
| Dec 31, 2020 | -343,640.49 |
| Sep 30, 2020 | 324,933.45 |
| Jun 30, 2020 | -499,794.34 |